NuVasive, Inc. has officially unveiled MAGEC X, the newest offering in its Early Onset Scoliosis (EOS) procedural solutions portfolio, at the recent annual meeting of the Pediatric Orthopaedic Society of North America.
Upgraded MAGEC X for Early Onset Scoliosis
1 min read Premium comments
#nuvasiveSecondary#knee#magec
According to NuVasive, the new MAGEC X features a strong, smart and sleek design with a new 5.0mm rod option that offers 68% improved fatigue-strength performance over the previous 4.5mm option.
The internal rod mechanism of the previous product generation has been redesigned with a robust actuator seal, a reinforced locking pin and anti-jam protection. Aesthetic improvements to the new design enhance ease-of-use by providing visual indicators for cutting and implanting the rod.
“The MAGEC system continues to be the gold standard for the minimally-invasive treatment of Early Onset Scoliosis,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive.
“With MAGEC X, we have found a way to take an exceptional solution to another level through internal rod mechanism advancements to boost performance and by providing surgeons with expanded size options. With MAGEC X clinicians can treat a greater variety of EOS cases—giving them a less invasive and traumatic experience as they work to achieve a straighter spine and a higher quality of life.”
Matt Link told OTW, “With the launch of MAGEC X, NuVasive has improved an already exceptional solution with an advanced internal rod mechanism and expanded size options—boosting performance and delivering improved strength, a more robust actuator seal, a reinforced locking pin and anti-jam protection. MAGEC X allows clinicians to treat a greater variety of early onset scoliosis cases and provide a less invasive experience as they work to achieve spinal alignment and a higher quality of life.”
“NuVasive MAGEC X is the culmination of 10 years of innovation and research. The system’s magnetically-controlled rods reduce the number of repetitive, invasive and traumatic surgeries that a child must go through to treat early onset scoliosis, setting the stage for a better clinical outcome and patient experience throughout the patient journey.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.